Brian Robb Douglass - 07 May 2026 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Reporting relationship: CHIEF PRODUCT OFFICER
Issuer ticker: RGEN
Reported as of: 07 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 May 2026, 14:39:43 UTC
Prior SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Carmichael (Attorney in Fact)

Key filing fact

Brian Robb Douglass filed Form 4 for REPLIGEN CORP (RGEN) on 08 May 2026.

Key facts

This page summarizes Brian Robb Douglass's Form 4 filing for REPLIGEN CORP (RGEN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 May 2026, 14:39.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002104618 Primary reporting owner

Douglass Brian Robb

Relationship: CHIEF PRODUCT OFFICER
Address: C/O REPLIGEN CORPORATION, 41 SEYON ST., BLDG 1, STE 100, WALTHAM
Signature: /s/ Jennifer Carmichael (Attorney in Fact)
Signature date: 08 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RGEN transaction

Common Stock

Tax liability

Transaction value
Shares: -334
Change %: -4%
Price: $126.43^*
Shares after: 7,985
Date: 07 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.